quantisnow
FeedTopReportsPricing
⌘K
Live feed
12:35:00·41d
PRRelease
Johnson & Johnson logo

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

JNJ· Johnson & Johnson
Health Care
Original source

Companies

  • JNJ
    Johnson & Johnson
    Health Care

Recent analyst ratings

  • Apr 8UpdateTD Cowen$250.00
  • Jan 28UpdateMorgan Stanley$262.00
  • Nov 13UpdateScotiabank$230.00
  • Oct 20UpdateDaiwa Securities$203.00
  • Oct 3UpdateWells Fargo$212.00
  • Sep 23UpdateGuggenheim$206.00

Related

  • SEC1d
    SEC Form 10-Q filed by Johnson & Johnson
  • PR1d
    IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
  • PR2d
    Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
  • PR2d
    Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026
  • PR7d
    The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
  • PR8d
    Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
  • SEC9d
    Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
  • PR9d
    Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022